Want to see MWAI full AI Analyst Report?
Top Page
MedWellAI
(OTC:MWAI)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.34
▼(-2.86% Downside)
Action:Reiterated
Date:07/01/26
The score is primarily held down by weak financial performance, including volatile/sharply declining revenue, ongoing heavy losses, continued cash burn, and multi-year negative shareholder equity. Technical analysis is neutral due to missing indicators, and valuation is below average given a negative P/E and no dividend yield data.
Positive Factors
Low absolute debt burden
Low nominal debt (≈$0.6M) reduces fixed financing costs and interest burden, providing structural flexibility to manage short-term obligations and pursue restructuring or product investment. Over a 2–6 month horizon this limits default risk versus highly leveraged peers and eases near-term refinancing pressure.
Negative Factors
Severe revenue decline
A ~61% YoY revenue drop is a durable red flag: it erodes unit economics, undercuts pricing power and market position, and impairs ability to leverage fixed-cost infrastructure. Such a large structural top-line contraction makes achieving sustainable margins and predictable cash generation much harder over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low absolute debt burden
Low nominal debt (≈$0.6M) reduces fixed financing costs and interest burden, providing structural flexibility to manage short-term obligations and pursue restructuring or product investment. Over a 2–6 month horizon this limits default risk versus highly leveraged peers and eases near-term refinancing pressure.
Read all positive factors
MedWellAI (MWAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.42M
Dividend YieldN/A
Average Volume (3M)758.00
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth-5.68%
EPS Growth60.23%
CountryUS
Employees1
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)-0.36
Shares Outstanding6,536,580
10 Day Avg. Volume719
30 Day Avg. Volume758
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.81
Price to Sales (P/S)3.42
P/FCF Ratio-2.17
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue3.00
Enterprise Value/Gross Profit3.53
Enterprise Value/Ebitda-0.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MedWellAI Business Overview & Revenue Model
Company Description
MedWellAI Inc., through its subsidiary, develops, acquires, operates, and invests in businesses. It provides AI-driven healthcare and wellness solutions. The company also offers a B2B e-commerce platform for distributing pharmaceutical products, p...
MedWellAI Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 689.71K | 594.77K | 5.86M | 5.86M | 3.86M | 6.55M |
| Gross Profit | 585.91K | 586.67K | 1.93M | 1.93M | 1.16M | 931.01K |
| EBITDA | -2.65M | -2.87M | -8.61M | -21.59M | 1.07M | -21.59M |
| Net Income | -3.04M | -3.61M | -11.52M | -11.52M | -565.51K | -22.43M |
Balance Sheet | ||||||
| Total Assets | 549.87K | 805.50K | 3.94M | 6.59M | 16.28M | 13.36M |
| Cash, Cash Equivalents and Short-Term Investments | 223.22K | 401.31K | 57.81K | 258.00K | 490.28K | 2.10M |
| Total Debt | 600.30K | 604.27K | 500.00K | 500.00K | 385.44K | 19.15K |
| Total Liabilities | 7.61M | 3.14M | 7.81M | 7.10M | 5.69M | 4.40M |
| Stockholders Equity | -7.06M | -2.50M | -3.87M | -509.88K | 10.59M | 8.96M |
Cash Flow | ||||||
| Free Cash Flow | -861.21K | -937.55K | -4.13M | -3.73M | -9.88M | -19.90M |
| Operating Cash Flow | -861.21K | -935.31K | -4.13M | -3.43M | 55.45K | -1.57M |
| Investing Cash Flow | 247.90K | 1.19M | 4.17M | 4.17M | -2.27M | -9.12M |
| Financing Cash Flow | 0.00 | 0.00 | -243.15K | -243.15K | 604.92K | 12.78M |
MedWellAI Risk Analysis
MedWellAI disclosed 12 risk factors in its most recent earnings report. MedWellAI reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MedWellAI Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
47 Neutral | $64.23M | -13.90 | -20.95% | ― | 22.98% | -362.10% | |
44 Neutral | $2.42M | -1.64 | 47.04% | ― | -5.68% | 60.23% | |
44 Neutral | $4.29M | -0.35 | -138.21% | ― | 117.68% | -0.39% | |
41 Neutral | $10.87M | -0.89 | 36.60% | ― | -1.85% | 55.50% | |
37 Underperform | $434.06K | >-0.01 | 152.17% | ― | -82.43% | -299.27% |
* Financial Sector Average
MWAI
MedWellAI
0.37
-0.15
-28.85%
NVNI
Nvni Group
0.93
-4.56
-83.06%
AIXI
Xiao-I Corp. ADR
0.47
-27.73
-98.33%
SPPL
Simpple Ltd.
1.81
-1.24
-40.66%
HIT
Health In Tech, Inc. Class A
0.98
-1.73
-63.84%
CSAI
Cloudastructure, Inc. Class A
4.91
-36.19
-88.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.